Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 112

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 112
---
, 2024, and the related statements of operations, changes in shareholders’
deficit, and cash flows for the period from May 23, 2024 (inception) through December 31, 2024, and the related notes (collectively referred
to as the “financial statements”). In our opinion, the financial statements presents fairly, in all material respects, the
financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows the period from May 23,
2024 (inception) through December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Matter

The accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company expects to continue to incur
significant costs in pursuit of its financing and acquisition plans, the Company’s business plan is dependent on the completion
of a business combination within a prescribed period of time and if not completed will cease all operations except for the purpose of
liquidating. The date for mandatory liquidation and subsequent dissolution raises substantial doubt about its ability to continue as a
going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we